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ABSTRACT
Interleukin-17 (IL-17), the signature cytokine produced by T helper 17 
(Th17) cells, plays crucial roles in host defense against microbial organisms 
and  in  the  development  of  inflammatory  diseases.  IL-17  promotes  the 
expression of cytokines and proteins involved in inflammatory responses, via 
the  induction  of  gene  transcription  and  post-transcription  stabilization  of 
mRNA. These  functions  are  mediated  by  CIKS,  an  adaptor  protein  that  is 
recruited to the receptor after IL-17 stimulation. 
We shows here that LRRFIP1 isoform 3 is a new CIKS interactor. Over-
expression of LRRFIP1 isoform 3 blocks the IL-17 induced gene expression, 
via  down-regulation  of  NF-κB  and  AP-1.  Accordingly,  down-regulation  of 
LRRFIP1 enhanced the expression of  cxcl1 and  il-6 after IL-17 stimulation. 
LRRFIP 1 isoform 3 exerts this function by interfering with the recruitment of 
CIKS to the cytoplasmic domain of the IL-17 receptor.  
Collectively  our  finding  defines  a  new  mechanism  regulating  the 
inflammatory response.
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BACKGROUND
TH17 linfocites
T helper  17  cells  (Th17)  are  a  subset  of  T  helper  cells  producing 
interleukin  17  (IL-17)  developmentally  distinct  from  Th1  and  Th2  cells 
(Harrington et al., 2005; Park et al., 2005).
Originally IL-17 was thought to be produced exclusively by T cells, but 
it  is  now  known  to  be  secreted  by  a  variety  of  innate  cells  including 
macrophages, mast cells, dendritic cells, and natural killer (Korn et al., 2009).
Whereas it was known for decades that IL-12 induces Th1 cells (IFN-
producers) and IL-4 induces Th2 cells (IL-4, IL-5 and IL-13 producers), it was 
only  recently  demonstrated  that  Th17  cells  differentiate  upon  exposure  to 
combinations of IL-6 and transforming growth factor-β (TGF-β). 
Initial differentiation fase of mouse TH17 cells requires the presence of 
transforming growth factor-β (TGFβ) and IL 6 as well  as STAT3 signalling‐  
(Bettelli et al., 2007). Analogous to the differentiation of TH1 and TH2 cell 
lineages,  TH17 cells  require  additional  lineage-specific transcription factors. 
Both retinoid-related orphan receptor-α (RORα) and RORγt are required for 
TH17 cell differentiation (Dong, 2008a), and these transcription factors can be 
induced by the combined presence of TGFβ and IL 6 in naive T cells (Chung et‐  
al., 2009; Martin et al., 2009; Sutton et al., 2009). 
It  has  been  argued  that  differentiation  of  human  TH17  cells  could 
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Figure 1: General scheme of T-helper-cell differentiation. Nat Rev Immunol. 2008 May; 
8(5):337-48.
potentially occur independently of TGFβ, as a combination of IL 23 and IL 1β‐ ‐  
has been shown to be sufficient to induce TH17 cell differentiation. However, 
murine and human TH17 cells are very similar; both cell types express IL 17A,‐  
IL 17F, IL 21, IL 22, IL 23R and IL 1R1, and require RORα and RORγt as‐ ‐ ‐ ‐ ‐  
crucial transcription factors for their differentiation (Ghoreschi et al., 2010).
IL-17 is essential for host defence against many microbes, particularly 
extracellular bacteria and fungi, in particular for mucosal epithelia (O’Quinn et 
al.,  2008).  Interleukin-17  and  other  Th17  cytokines  are  linked  to  the 
pathogenesis  of  diverse  autoimmune  and  inflammatory  diseases.  The  IL-17 
receptor  is  expressed  ubiquitously,  and  hence  most  cells  can  potentially 
respond to this cytokine (Yao et al., 1997).
It has been noted that IL 17A expression can be induced within hours‐  
after infection or immunization with an adjuvant and before the differentiation 
of TH17 cells from native progenitors, which takes several days. This suggests 
that cells other than TH17 cells can produce IL 17. ‐
Mast cells also produce several members of the IL 17 family. Following‐  
Fcε receptor I mediated activation, mast cells produce substantial amounts of‐  
IL 17E,  which can influence TH2 type responses (Ikeda et  al.,  2003).  Mast‐ ‐  
cells also produce IL 17A in response to their activation by Toll-like receptor 2‐  
(Mrabet-Dahbi et al., 2009); this has been shown in several diseases, including 
asthma, psoriasis (Lin et al., 2011), rheumatoid arthritis (Hueber et al., 2010; 
Moran et al., 2011), and amyotrophic lateral sclerosis (Fiala et al., 2010). 
The respective contribution of IL 17 produced by these different cell‐  
types to disease pathology is still unknown. 
Interleukin-17 mediates adverse effects in many autoimmune diseases. 
Before the discovery of the Th17 it was considered that Th1, Th2 and B cells 
were the main mediators of pathology in autoimmunity. 
Based  on  these  observations,  inhibitors  —  mostly  monoclonal 
antibodies — have been designed, and the results of these clinical trials are 
now being released.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder 
that  may  affect  many  tissues  and  organs,  but  principally  attacks  flexible 
(synovial) joints. It can be a disabling and painful condition, which can lead to 
substantial loss of functioning and mobility.
Inflammatory infiltrate of the joint synovium membrane leads to bone 
and cartilage destruction. The presence of IL 17 positive cells in the affected‐ ‐  
synovium and the production of functionally active IL 17 by this tissue was‐  
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first demonstrated in this disorder (Lubberts et al., 2002).
Interleukin-17 induces pro-inflammatory cytokines such as TNFα, IL-
1β and IL-6 from cartilage, synoviocytes, macrophages and bone cells (Shen 
and Gaffen, 2008). Collectively, these pro-inflammatory cytokines contribute 
to RA increase and also establish a chronic inflammatory state by a positive 
feedback  loop  wherein  IL-17-induced  IL-6  maintains  the  Th17  T-cell 
population (Ogura et al., 2008). The IL-17 also stimulates the production of 
multiple chemokines, including IL-8/CXCL8, CXCL1, CXCL2, CCL20, CCL2 
and CCL7 (Fossiez et al., 1996; Park et al., 2005; Shen and Gaffen, 2008; Shen 
et  al.,  2005a).  These  serve  to  recruit  neutrophils,  macrophages  and 
lymphocytes to the synovium, thereby enhancing inflammation. 
Inhibition  of  IL 17 with  antibodies  against  the  ligand IL 17A or  its‐ ‐  
receptor  IL 17RA protected  against  the  development  and  consequences  of‐  
arthritis (Lubberts et al., 2004). Furthermore, mice lacking IL 17RA develop a‐  
very mild form of experimental arthritis.
Psoriasis 
Psoriasis  is  a  chronic  inflammatory  skin  disorder  characterized  by 
dermal  hyperplasia.  The  key  histological  features  of  psoriatic  skin  are 
epidermal  keratinocyte  hyperproliferation,  vascular  proliferation  and 
infiltration of Dentritic Cells, macrophages, neutrophils and T cells (Nestle et 
al., 2009).
Psoriasis has been successfully treated using TNFα inhibitors in some 
but not all  patients.  Skin biopsy samples taken from patients with psoriasis 
showed high expression of IL 17 together with high expression of IL 23, IL 22‐ ‐ ‐  
and IL 6 (Zheng et  al.,  2007).  Furthermore,  increased numbers of TH1 and‐  
TH17 cells were found in blood and skin lesions of patients, showing a positive 
correlation  with  disease  activity  (Lowes  et  al.,  2008).  Local  production  of 
TH17  cytokines  within  the  plaques  appears  to  contribute  to  the  increased 
production of chemokine CC motif ligand 20 (CCL20), a key chemokine that is 
necessary for the migration of TH17 cells (Harper et al., 2009). Mast cells and 
neutrophils  represent  additional  sources  of IL 17 in skin that  is  affected by‐  
psoriasis (Lin et al., 2011). 
Multiple sclerosis 
Multiple sclerosis is a chronic inflammatory disease that leads to brain 
inflammation in which the myelin around the axons of the brain and spinal 
cord are damaged, leading to demyelination leading to a broad spectrum of 
signs and symptoms
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Experimental  autoimmune  encephalomyelitis  (EAE)  is  a  model  of 
multiple sclerosis, a T-cell-mediated autoimmune disease of the central nervous 
system. It is elicited by immunization of neuroantigens, such as myelin basic 
protein and proteolipid protein. As with many other autoimmune conditions, 
Th1 cells were long thought to be responsible for EAE pathology, despite the 
fact that IFN-/-, IFNcR-/- and IL-12p35-/- mice were susceptible (Becher et al., 
2002; Ferber et al., 1996; Zhang et al., 2003). Landmark studies comparing the 
IL-12p35-/- and IL-23p19-/- mice showed clearly that the Th17 path-way was 
responsible for pathology (Langrish et al., 2005).
Further evidence for the role of Th17 cells in driving EAE was shown 
in STAT6-/- / T-bet-/- doubly deficient mice, lacking Th1 and Th2 cells (Das et 
al., 2009). IL-17 drive the tight junctions distruption that form the blood–brain 
barrier,  enabling Th17 cells  to  migrate  into the central  nervous system and 
cause neuronal  damage (Kebir  et  al.,  2007).  Furthermore,  EAE in the mice 
could be ameliorated by treatment with anti-IL-17 antibodies. 
Asthma
Asthma is a common airway disorder that is characterized by chronic 
airway inflammation, mucus production, and airway hyperresponsiveness with 
airway remodeling. 
Mouse models of asthma have yielded significant new insights recently. 
In  particular,  the  cytokine  IL-17E  (IL-25)  has  been  shown  to  have  a  role 
(Tamachi et al., 2006).
IL-17E  was  proposed  to  initiate  and  maintain  Th2  responses. 
Furthermore,  by  directly  and/or  indirectly  inducing  the  expression  of,  in 
particular, IL-13 and IL-5, IL-17E may be responsible for the observed mucus 
production  and  lung  infiltration  of  eosinophils  during  allergic  reactions 
(Claudio et al., 2009).
In asthmatic patients, IL-17 expression has been shown to increase in 
sputum,  lung  cells,  bronchoalveolar  lavage  fluids,  and  peripheral  blood 
(Barczyk et al., 2003).
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Interleukin 17 Family
The IL-17 gene and IL 17 protein were first discovered as a product of‐  
T cells in rodents, but it was not immediately recognized as a cytokine, owing 
to its unusual amino acid sequence (Rouvier et al., 1993).
It is well established that IL 17 activity contributes to various aspects of‐  
acute  inflammation.  The  IL 17 mediated  release  of  IL 6  and  IL 8  from‐ ‐ ‐ ‐  
mesenchymal cells leads to fever, an acute phase response (caused by IL 6) and‐  
the accumulation of neutrophils in blood and tissue (caused by IL 8)(Fossiez et‐  
al.,  1996). IL 17 activity also contributes to chronic inflammation (Miossec,‐  
2003), which is often — but not always — associated with matrix destruction.
The IL 17 molecule is composed of two monomers that are linked by‐  
intramolecular  disulphide  bonds  on  cysteine  residues  to  form  a  homo  or 
eterodimer. IL 17 is now formally referred to as IL 17A in the literature and is‐ ‐  
the founding member of the IL 17 family, which is composed of six members‐  
— from IL 17A, IL-17B, IL-17C, IL-17D, IL-17E (also known as IL-25), and‐  
IL 17F (Aggarwal and Gurney, 2002). ‐
IL 17A and IL 17F are the best characterized cytokines of the IL 17‐ ‐ ‐  
cytokine family. Both are covalent homodimers, and recent findings show that 
they also form IL 17A–IL 17F heterodimers (Chang and Dong, 2007).‐ ‐
IL 17A, IL 17F and the IL 17A–IL 17F heterodimer signal through the‐ ‐ ‐ ‐  
same receptor subunits: IL 17RA and IL 17RC (Kuestner et al., 2007; Wright‐ ‐  
et al., 2008). Results from mouse models, comparing IL-17A-/- and IL-17F-/- 
mice, indicate that some of the pro-inflammatory functions are not identical: 
IL 17A has a more important role in driving autoimmunity than IL 17F (Yang‐ ‐  
et al., 2008). 
This  effect  is  probably  due  to  more  activity  of  IL-17A in  inducing 
inflammation: IL 17F induced responses are  10–30 fold weaker  in  terms of‐ ‐  
downstream  gene  activation  than  those  of  IL 17A,  with  IL 17A–IL 17F‐ ‐ ‐  
heterodimers acting at an intermediate level (McAllister et al., 2005).
In  contrast  to  the  other  members,  IL 17E  (IL 25)  induces  allergic‐ ‐  
responses and activation of the TH2 pathway and it is produced by mucosal 
epithelial cells and many immune cell types (Wang et al., 2007). Moreover, IL‐
17E inhibits Th17 cell development by inducing the expression of IL 13 by‐  
dendritic  cells  (DCs)  or  by  inhibiting  IL 23  production  (Dong,  2008b;‐  
Kleinschek et al., 2007).
IL 17B, IL 17C and IL 17D functions are poorly defined .‐ ‐ ‐
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IL-17 Receptors
The first receptor to be identified for IL 17 was initially referred as IL‐ ‐
17  receptor  (IL 17R)  but  is  now  known  as  IL 17RA (Yao  et  al.,  1995).‐ ‐  
Afterwards  additional  receptor  components,  required  to  form  a  functional 
receptor complex for IL 17 signaling, were identify (Yao et al., 1997). ‐
Four additional  receptors  have been identified in  the IL 17R family,‐  
based on sequence homology to IL 17RA: IL 17RB, IL 17RC, IL 17RD and‐ ‐ ‐ ‐  
IL 17RE, thus IL 17RA appears to be a common receptor chain for the IL 17‐ ‐ ‐  
family of ligands. 
All  receptor  subunits  are  single  transmembrane  domain containing‐  
proteins, these receptor subunits contain certain conserved structural motifs, 
including  an  extracellular  fibronectin  III like  domain  and  a  cytoplasmic‐  
domain named SEFIR, a member of STIR-domain superfamily. 
STIR-domain superfamily comprising TIR (Toll/Il-1 Receptor) domain, 
and SEFIR (SEF/IL 17R) domain. ‐
TIR domain has three 'boxes'  of conserved residues and a important 
binding loop named BB-loop, SEFIR domain keep the same structure of TIR 
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Figure 2: IL-17R family ligand–receptor relationships and main structural features. Nat Rev 
Immunol. 2009 Aug;9(8):556-67.
domain, but lack the TIR box 3 subdomain and the BB loop (Novatchkova et‐  
al.,  2003).  However,  a  region  at  the  carboxy terminal  side  of  the  SEFIR‐  
domain in IL 17RA has marked sequence homology to BB loops. Deletion or‐ ‐  
point mutations in this region render IL 17RA non functional, so this motif is‐ ‐  
referred to as a TIR like loop (TILL)(Maitra et al., 2007; Shen et al., 2009). ‐
Surprisingly,  although  all  IL 17Rs  have  a  SEFIR  motif,  the  TILL‐  
domain  seems to  be unique  to  IL 17RA,  perhaps  explaining  why IL 17RA‐ ‐  
functions as a common subunit shared by several receptors in the family. 
As mentioned IL 17RA is necessary for signal transduction mediated by‐  
IL 17A, IL 17A–IL 17F and IL 17F (Hymowitz et al., 2001). Indeed, IL 17RA‐ ‐ ‐ ‐ ‐  
pairs  with IL 17RC to induce  responses  to  IL 17A and IL 17F (Toy et  al.,‐ ‐ ‐  
2006).  Similarly,  IL-17RA–/–  mice  are  refractory  to  the  effects  of  IL 17E,‐  
suggesting that IL 17RA is also a component of this receptor complex (Rickel‐  
et al., 2008). 
IL 17RA is  expressed  ubiquitously,  with  particularly  high  levels  in‐  
haematopoietic  tissues  (Ishigame et  al.,  2009;  Yao et  al.,  1995),  but  only a 
limited  number  of  IL 17A induced  genes  has  been  documented  in‐ ‐  
lymphocytes, and these genes are distinct from those induced by IL 17A in‐  
other cell types (Hsu et al., 2008; Ishigame et al., 2009), like endothelial cells 
and fibroblasts.
Another  function  of  IL 17RA seems to  limit  signalling  by  receptor‐ ‐
mediated internalization of the ligand. Indeed, surface expression of IL 17RA‐  
rapidly decreases after IL 17A binding (Lindemann et al., 2008). ‐
The precise stoichiometry of the IL 17A binding receptor complex has‐ ‐  
not been determined, but some data suggest the existence of a trimeric complex 
containing two IL 17RA subunits and one IL 17RC subunit (You et al., 2006).‐ ‐
In contrast to IL 17RA, IL 17RC expression is low in haematopoietic‐ ‐  
tissues and high in non immune cells of the prostate, liver, kidney, thyroid and‐  
joints  (Haudenschild  et  al.,  2002;  Kuestner  et  al.,  2007).  This  differential 
expression of IL 17R subunits is coherent with a mechanism for tissue specific‐ ‐  
signalling by IL 17A and/or IL 17F.‐ ‐
IL 17RB  instead  binds  both  IL 17B  and  IL 17E.  This  subunit  is‐ ‐ ‐  
expressed by various endocrine tissues as well as kidney, liver and Th2 cells 
(Lee et al., 2001). Recent evidence indicates that IL 17RB pairs with IL 17RA‐ ‐  
to form a functional receptor complex for IL 17E (Rickel et  al.,  2008). IL‐ ‐
17RB is the one IL-17R that has a TRAF6 binding motif in its cytoplasmic tail‐  
(Maezawa et al., 2006). 
IL 17RD  and  IL-17RE  has  no  known  ligand  and  their  function  is‐  
unknown.
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IL-17: molecual pathway
IL-17 stimulation leads to two major biological responses: 1) de novo 
transcription  and,  2)  stabilization  of  mRNA.  Both  biological  responses  are 
medieted by CIKS (Sun et al., 2011) (also known as ACT1 or TRAF3IP2) that 
is recruited to the receptor after IL-17 stimulation. Indeed genetic ablation of 
CIKS gene in mice, leads to unresponsiveness to IL-17 stimulation (Claudio et 
al., 2009).
CIKS contains a SEFIR domain, an E3 ubiquitin ligase domain (Liu et 
al.,  2009),  and a binding site  to TRAF6 (Sønder  et  al.,  2012).  The binding 
between  CIKS  and  IL-17RA  is  mediated  by  a  SEFIR-SEFIR  domains 
interaction. In particular CIKS binds to the CC  loop region of the cytoplasmicʹ  
tail of IL 17RA. ‐
After receptor binding CIKS recruits and ubiquitinates TRAF6 through 
K63 in a U-box – dependent manner (Liu et al., 2009). 
complex  (Deng  et  al.,  2000).  Like  the  activation  of  NF-κB  by  TLR,  IKK 
complex  induces  the  phosphorylation,  degradation  of  IκBα  and  subsequent 
activation of NF-κB (Liu et al.,  2009; Schwandner et al.,  2000). Some data 
demonstrate that NF-κB p65 and p50 subunits quickly associate with NF-κB 
response  element  upon IL-17 stimulation  (Ruddy et  al.,  2004;  Shen  et  al., 
2006). There is no evidence of activation of the noncanonical NF-κB subunits. 
Interestingly,  IL-17 also induces  expression of IκBζ (Shen et  al.,  2005a),  a 
positive  regulator  of  NF-κB  activation  (Yamamoto  et  al.,  2004).  Recently, 
additional  evidence  suggests  that  IκBζ  plays  an  important  role  in  IL-17–
induced expression of human β-defensin 2 and neutrophil gelatinase-associated 
lipocalin (Karlsen et al., 2010).
IL-17  signaling  also  activates  C/EBPs.  Among  all  C/EBP  family 
members, only C/EBP- β and C/EBP-δ are transcriptionally up-regulated by 
IL-17 (Shen et al., 2005b). The cooperation of NF-κB and C/EBPs can only 
partially explain the synergistic effect of IL-17 and TNFα. 
IL-17A also activates the MAPK pathway. Within 30 minutes of IL- 
17A stimulation,  ERK is  rapidly phosphorylated  and then regulates  various 
downstream signaling components, including NF-κB, C/EBP, and AP1 (Maitra 
et al., 2007).
Expression of the IL-17 target genes dependent
IL-17 target genes  can be categorized into five major groups: 
1) chemokines;
2) proinflammatory cytokines and inflammatory mediator related genes; 
3) antimicrobial peptides; 
4) tissue remodeling genes; 
5) signaling components such as C/EBPβ , C/EBPδ , and IκBζ
CXCL1, CXCL2, and CXCL5 are the major mediators of the IL-17–
induced neutrophil response in host defense and various inflammatory disease 
models.  IL-17F alone  or  in  combination  with  IFNγ can stimulate  CXCL10 
production in bronchial epithelial  cells (Kawaguchi et al., 2007). Other CXC 
chemokines such as CXCL6, CXCL8, and CXCL12 are also regulated by IL-
17. CCL2 and CCL20 are among the few CC chemokines up-regulated by IL-
17 (Kao et al., 2005). 
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IL-17A  induces  production  of  other  proinflammatory  cytokines  in 
various cell types. For example, IL-6 is one of the earliest target genes reported 
in  IL-17A–stimulated  fibroblasts  (Yao  et  al.,  1995). G-CSF  is  another 
important cytokine that is induced by the IL-17 pathway. 
IL-17  (like  IL-1  and  TLR)  also  induce  a  anti-inflammatory  RNase: 
Zc3h12a (also know as MCPIP or MCPIP1) that selectively degrades specific 
target mRNA, like IL-1, IL-6 or IL-12, to modulates the immune response and 
inflammation  (Huang  et  al.,  2012).  Zc3h12a  recognizes  the  3'-untranslated 
region (UTR) of the mRNA, it is able to cleaved the mRNA and it is required 
for normal decay of mRNA. It triggers apoptosis and promotes angiogenesis in 
response to the binding of CCL2 to CCR2 (Matsushita et al., 2009). Zc3h12 is 
also a Interferon Stimulated Genes (IGSs) induced by interferon-γ, and it has 
been hypothesized to suppress the antiviral state (Abe et al., 2011).
Antimicrobial peptides are important mediators of innate immunity; and 
IL-17A is  a  potent  inducer  of  various  antimicrobial  peptides.  Lipocalin  2 
(24p3) plays an important role in host defense against E. coli and Klebsiella 
pneumoniae by limiting bacterial siderophores to bind free  iron (Goetz et al., 
2002). In fibroblast cells, IL-17A alone or with TNFα results in quick induction 
of 24p3 protein (Shen et al., 2006). As another example, human β-defensin 2 
(hBD2) is  an antimicrobial  peptide and a  chemo-attractant  to  CCR6+ cells. 
hBD2 is markedly up-regulated by IL-17A in human airway epithelium and 
during virus infection (Kao et al., 2008).
IL-17A also induces expression of MMPs, including MMP1, MMP2, 
MMP9,  and  MMP13,  which  are  the  major  players  in  extracellular  matrix 
degradation and bone resorption (Sylvester et al., 2004). Mice lacking IL-17RA 
fail  to  express  MMPs in  streptococcal  cell  wall  induced-arthritis  and show 
amelioration of cartilage destruction (Koenders et al., 2005).
Leucine-Rich Repeat Interacting Protein-1 – LRRFIP1 
Leucine-rich  repeat  in  Flightless-1  interaction  protein  1/GC-binding 
factor  2  (LRRFIP1/GCF2)  belongs  to  a  small  family  of  proteins  whose 
function and regulation have been poorly studied. It was originally identified 
either as repressor of the epidermal growth factor receptor gene (Reed et al., 
1998) or as interactor of the mammalian homolog of  Drosophila Flightless I 
(Fliih-I),  a  member  of  gelsolin  family  (Liu  and  Yin,  1998).  LRRFIP1  was 
found in both nuclear and cytoplasmatic compartments in cells (Ariake et al., 
2012; Ohtsuka et al., 2011).
The study of LRRFIP1 gene and cDNA, showed that the gene  encodes 
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different  splice  isoforms  in  human  and  mouse  species,  which  may  be 
differentially expressed and regulated (Fong and de Couet, 1999; Liu and Yin, 
1998;  Reed et  al.,  1998;  Rikiyama et  al.,  2003;  Suriano et  al.,  2005).  Five 
human  LRRFIP1  isoforms  have  been  reported  and  three  of  them,  namely, 
GCF2,  LRRFIP1  and  TAR  RNA  interacting  protein  (TRIP),  have  been 
described as proteins functionally different. Indeed, GCF2 is a trascriptional 
repressor, LRRFIP1 is a modulator of the innate immune response translation, 
and  TRIP  is  an  RNA-binding  protein  and  possible  regulator  of  mRNA 
translation  (Gubern  et  al.).  Northern  blot  analysis  showed  that  LRRFIP1 
mRNA was  differentially  expressed  in  many  human  tissues  and  cell  lines. 
LRRFIP1  mRNA was  expressed  in  most  human  tissues  with  the  highest 
expression level in peripheral blood leukocytes and lowest expression in brain 
and testis.  Therefore,  LRRFIP1 protein is present at  high levels in Burkitts' 
lymphoma  and  several  other  cancer  cell  lines  (Rikiyama  et  al.,  2003). 
LRRFIP1 has been indentified as one of the cancer-associated genes (Sjöblom 
et  al.,  2006)  which  promotes  cell  invasion  and metastasis  (Arakawa et  al., 
2010).  Finally,  LRRFIP1 plays  also  a  role  in  the  formation  of  thrombosis. 
Indeed, its shRNA might represent a promising prevention strategy for deep 
vein thrombosis(Yin et al., 2013). 
LRRFIP1 isoform1 contains an N-terminal domain of unknown 
function, a conserved 87-amino acid domain predicted to be a coiled coil, and a 
nucleic acid binding domain. The coiled coil domain, which is found in all 
LRRFIP1 genes (isoform 1, isoform 2 and isoform 3), is highly conserved 
across mammalian species and is required for interaction with other proteins 
such as the leucine-rich repeat (LRR) domain of Fliih-I (Fong and de Couet, 
1999).
With regard to the mouse isoforms, three different proteins have been 
reported, two of which, Fli-I leucine-rich repeat associated protein 1 (Flap-1) 
and Lrrfip1, have been studied.  Dai et al. found that Flap-1 compete with 
Fliih-I at the same binding site at MyD88, suggesting a functional role in TLR-
mediated NF-B activation and cytokine production(Dai et al., 2009). On the 
other hand, it is able to directly bind dsRNA as well as GC-rich ds-DNA. 
Indeed, LRRFIP1 detects exogenous dsDNA through its nucleic acid-binding 
domain and increases the production of type I interferon, possibly by 
promoting -catenin activation (Yang et al., 2010). Both Flap-1 and Lrrfip1 
directly interacts with -catenin and activates -catenin-dependent trascription 
activity(Lee and Stallcup, 2006). 
The three isoforms appear to be different from each other, as shown in 
fig. 4A. Isoform 1 and isoform 2 have the same exon 1 which is different from 
exon 1 of isoform 3. Moreover, the three isoforms present common exons and 
there are homology between the C-term of isoform 2 and isoform 3. In fig. 4B, 
is shown the schematic representation of the three different proteins that are 
composed, respectively, by 729, 628 and 428 aa. Only the isoform 1 contained 
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the  nuclear  localization  signal  (NLS)  and  the  RNA-binding  domain.  All 
isoforms  contained  coiled-coil  domain  essential  of  interaction  with  other 
proteins. 
Therefore, LRRFIP1 shows itself to be an interesting gene through 
which different isoforms may modulate multiple signaling pathways involved 
in different biological functions.
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Figure 4:A, schematic rappresentation of murine LRRFIP1 transcrip variants. Exons are 
shown as vertical bars. In blue are indicated the portions common to the three isoforms,in pink  
the exons common to isoform 1 and isoform 2 while in green are showed the exons common to 
isoform2 and isoform 3. B, schematic rappresentation of murine LRRFIP1 proteins. Isoform 1 
is 729 aa and presents a coiled-coil domain, a NLS and a DNA-binding domain. Isoform 2 is 
628 aa long and presents only a coiled-coil domain. Most of this domain is also present in 
isoform 3 that is 428 aa long.. 
AIM OF THE STUDY
IL-17  plays  a  critical  role  in  host  defense  against  different  pathogens  in 
mucosal epithelium. IL-17 induces and sustains tissue inflammation and drives 
the  immune  responses,  mainly  by  two  different  mechanisms.  The  first  is 
transcription  dependent  and  involves  transcription  of  genes  controlling 
inflammation,  the  second  is  dependent  upon  the  stabilization  of  different 
mRNA induced by other inflammatory cytokines, such as TNFα. 
In the last few years some of the mechanisms regulating these two functions 
have  been elucidated.  However,  much  remains  to  be  understood  about  this 
molecular pathway. The present study aims to indentify new protein involved 
in the IL-17 signaling, in order to unravel the molecular mechanism regulating 
the IL-17 dependent inflammatory responses.
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MATERIAL AND METHODS
Reagents, cell lines, and constructs. 
Recombinant  IL-17  and  TNF-alpha  were  from Peprotech,  and  were 
used  at  200ng/ml   and  2000U/ml,  respectively.  Anti-M2  (Flag)  was  from 
Sigma-Aldrich. 
HEK293, wild type mouse embryonic fibroblast (MEF), CIKS-/- MEF, 
were maintained in Dulbecco modified Eagle medium (DMED) supplemented 
with 10% fetal bovine serum (FBS; Sigma-Aldrich), antibiotics (100 µg/mL 
penicillin, 100 µg/mL streptomycin), and 1 mM L-glutamine (Invitrogen). WT 
and CIKS-/- MEF were a gift of U. Siebenlist (NIAID, NIH).
Single  stable  transfected  clones  were  generated  transfecting  plasmid 
encodes  HA-LRRFIP1  isoform3  and  the  single  clones  were  isolated  after 
selection with 5g/ml of puromycin.
The cDNA encoding CIKS and its mutants were previously described 
(PNAS, BBRC). The plasmids expressing LRRFIP1 isoform 2 or LRRFIP1 
isoform 3 were from OriGene . LRRFIP1 isoform 2 and LRRFIP1 isoform 3 
mutants  were  generated  by  PCR  and  cloned  in  pCDNA3.1-HA or  FLAG 
(Invitrogene).
RNA-interference (RNAi) and transfection.
Cells  were  transfected  with  small  interfering  RNA oligonucleotides 
(20nM  final  concentration)  and  Interferin  (PolyPlus)  according  to 
manufacturer’s instruction. The siRNA sequences used are:
Mouse LRRFIP1  5′-GGACCAGAUUCAGGAUGUA-3′
The  scrambled  control  was  from  Thermo  Scientific (siRNA  ON-
TARGETplus Non-targeting Pool #D-001810-10-05).
Seventy  two  hours  after  transfection  cells  were  collected  for  RNA 
extraction. 
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Lentivirus production and infections.
FLAG-CIKS  cDNA was  subcloned  into  pWPT  lentiviral  vector  at 
BamHI/SalI  sites.  The  construct  was  sequenced  to  confirm  correct  DNA 
sequence and orientation. Subconfluent 293T lentivirus packaging cells were 
cotransfected with either pWPT-GFP or CIKS-FLAG-pWPT and pMD2G and 
pCMV-R8.91  by  calcium  phosphate  precipitation.  After  24h  medium  was 
changed,  and  supernatant  was  harvested  after  48  and  72  hours.  Lentiviral 
supernatant, cleared of cell debris, was concentrated by centrifugation for 90 
min at 23000 rpm at 4°C. For transduction, CIKS-/- MEFs were plated on 12-
well  plate,  infected  with  lentiviruses  in  the  presence  of  10% foetal  bovine 
serum  and  8g/ml  polybrene  (Hexadimethrine  bromide;  Sigma-Aldrich, 
Milano, ITALY). 
Coimmunoprecipitation and immunoblot analysis.
CIKS-/- MEF reconstituted with FLAG-CIKS or with empty vector were 
left untreated or treated with IL-17 at different time points, were harvested by 
washing with ice-cold PBS, and then lysed with Lysis buffer (20 mM HEPES 
pH7.5, 150 mM NaCl,  1% Triton X-100, 10% Glycerol,  10mM NaF, 1mM 
Na3VO4)  freshly  supplemented  with  protease  inhibitors  cocktail  (Roche). 
Nuclear and cellular debris were removed by centrifugation at 14,000 x g for 
30 min at 4°C. Cell extracts were normalized for protein content, and incubated 
with 20 l of M2 beads for 3 hours at 4°C. Beads were washed five times with 
Lysis buffer, and boiled in SDS sample buffer, and the resulting supernatants 
were subjected to 10% SDS/PAGE. 
For  identification  of  the  CIKS-interacting  proteins,  100mg  of  cell 
extract from CIKS-/- and reconstituted MEF were incubated with 500 l of M2 
beads  (Sigma)  pre-washed  with  Glycine  pH3.0  to  eliminate  not  covalently 
bound antibody. After 3 hours incubation at 4°C, beads were washed four times 
with Lysis buffer,  2 times with High Salt  (1M NaCl) Lysis buffer.  Proteins 
were  eluted  from  the  beads  by  using  500l  of  3xFLAG  peptide  (Sigma) 
200mg/ml.  Eluated  proteins  were  sent  to  Scaloni  Andrea  (CNR)  for  mass 
spectrometry.
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RNA isolation and Real-Time PCR. 
Total  RNA was  extracted  by  using  TRIZOL  reagent  according  to 
manufacturer’s  instruction  (Invitrogene).  Real-time RT-PCR was carried  out 
with cDNAs reverse-transcribed from total RNA by using GoTaq qPCR Master 
Mix (Promega, Madison, WI, USA) and Bio-Rad CFX Manager software (Bio-
Rad, Segrate, MI, ITALY). The primers used were:
LRRFIP1 isoform 3: FW: 5'-GATGGACATGGGCACGCA-3'
REV: 5'-GTTACGGGAGCCCTTCTCAG-3'
GAPDH: FW: 5'-ATGGTGAAGGTCGGTGTGAAC-3' 
REV: 5'-CCATGTAGTTGAGGTCAATGAAG-3'
Cxcl1: FW: 5'-AGCCACCCGCTCGCTTCTCT-3' 
REV: 5'-GTCCCGAGCGAGACGAGACCA-3' 
IL6: FW: 5'-AAAGCCAGAGTCCTTCAGAGAGA-3' 
        REV: 5'-GGTCCTTAGCCACTCCTTCTGTG-3'
Luciferase assay.
Either the Ig-B-Luc or AP-1-Luc or ISRE-Luc were used as a reporter 
plasmids.  Cells  were  cotransfected  with  a  mixture  of  luciferase  reporter 
plasmid, the thymidine kinase promoter-renilla luciferase plasmid pRL-TK and 
various  amount  of  CIKS,  LRRFIP1  isoform3  constructs  by  using 
Lipofectamine reagent (Invitrogen). 24h after transfection, cells were harvested 
or  stimulated with IL-17 or TNF- for 4h and cell  extracts  were prepared. 
Luciferase  activity  were  measured  with  Dual-Luciferase  Reporter  Assay 
system  according  to  the  manufacturer’s  instruction  (Promega).  Data  were 
normalized for transfection efficiency by dividing the firefly luciferase activity 
by the renilla luciferase activity. 
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RESULTS
Identification  of  LRRFIP1  as  a  specific  CIKS-interacting 
protein.
In order to clarify the molecular mechanism regulating IL-17 signaling 
we decided to isolate new CIKS interactors. 
We  set  up  an  experimental  system  constituted  by  MEF  (Mouse 
embryonic  fibroblast)  isolated  from  CIKS-/- mice,  and  the  same  cells 
reconstituted by lentiviral infection, with FLAG-CIKS. 
The level of expression of FLAG-CIKS in the reconstituted cells, was 
comparable to the endogenous protein. In fact, no transcription of IL-17 
dependent genes was detected in unstimulated cells, while a strong 
transcriptional response was observed after IL-17 stimulation, comparable to 
that detected in wt MEF (Fig 5). In addition, when the cells were stimulated 
with IL-17 plus TNFα, there was a synergistic effect on mRNA levels. This 
effect was due to mRNA neo-synthesis through TNFα signaling, and to mRNA 
stabilization induced by IL-17 (Hartupee et al., 2007; Henness et al., 2004). As 
shown in figure 5 treatment of wt and reconstituted MEF with IL-17 results in 
upregulation of different IL-17 target genes: cxcl1 (B), ccl2 (C), cxcl5 (D), IL6 
(E), Lcn2 (F). In the absence of CIKS both the IL-17 dependent transcription 
and the IL-17 dependent mRNA stabilization were absent.
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Figure 5: Functional characterization of WT, CIKS-/-, and reconstituted MEF. Cells were 
stimulated with TNFα, IL-17 or both cytokines for 6 hours, RNA extracted and the level of the 
indicated RNAs were assessed by Real Time PCR.
To search for CIKS-interacting proteins, cell extracts from CIKS-/- and 
reconstituted MEF were immunoprecipited and analysed by mass spectrometry. 
We found about 30 interactors immunoprecipitated from the reconstituted cells 
but  not  in  the  CIKS-/- cells,  some  of  them  are  already  known  as  CIKS 
interactors, such as IKKε and SF2. 
One of the CIKS interactors we isolated was LRRFIP1. LRRFIP1 is a 
leucine  rich  repeat  interacting  protein,  involved  in  different  biological 
functions.  Three isoforms have been isolated in mice,  each with substantial 
differences  in  both  amino acid  sequence  and biological  functions.  We then 
identified which isoform was interacting with CIKS. We found that 36 peptides 
were common among the three different isoforms, no peptides were specific for 
isoform  1,  11  peptides  were  specific  to  isoform 2  and  3  and  18  peptides 
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Figure 6: Immunoprecipitation of FLAG-CIKS followed by mass spectrometry analysis. Cell 
lysates were immunoprecipitated with anti-FLAG Ab and eluted wit 3xFLAG peptide. The 
eluted proteins were separated by SDS-PAGE followed by silver stain.
belongs specifically to isoform 3 (tab. 1). This result suggest that the isoform 3, 
of LRRFIP1 is interacting with CIKS. 
LRRFIP1 ISOFORMS Peptides
Isoform 1 0
Isoform 2 and isoform 3 11
Isoform 3 18
All 3 isoforms 36
Table 1: peptides obtained by mass spectrometry analysis were compared with the aminoacid 
sequence of the 3 different isoforms of LRRFIP1. The number of peptides specific for a given 
isoform are indicated.
To confirm the interaction between CIKS and LRRFIP1, both isoforms 
2 and 3 of LRRFIP1 were cloned in pcDNA3.1 and transiently trasfected in 
HEK-293 cells.  As shown in figure 7 both isoforms of LRRFIP1 were co-
immunoprecipitating with FLAG-CIKS, but the interaction between CIKS and 
LRRFIP1 isoform 3 was stronger compared with the interaction between CIKS 
and  LRRFIP1  isoform  2.  From  this  result  we  decided  to  investigate  only 
LRRFIP1 isoform 3. 
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Mapping  of  the  interaction  between  CIKS  and  LRRFIP1 
isoform 3.
Next, we investigated the region of LRRFIP1 isoform 3 involved in the 
binding of CIKS, and the region of CIKS necessary to interact with LRRFIP1 
isoform 3. HEK-293 were transfected with different deletion mutants of CIKS 
together with LRRFIP1 isoform 3. We immunoprecipitated full lenght FLAG-
CIKS and its  deletion  mutants  demonstrating  that  both  N-term and C-term 
domains of CIKS were essential  for the binding to LRRFIP1 isoform 3,  as 
shown in fig 8. 
25
Figure 7: CIKS interacts with LRRFIP1 isoform2 and LRRFIP1 isoform 3. HEK293 were 
trasfected with expression plasmids encoding HA-tagged LRRFIP1 isoform2 or  HA-tagged 
LRRFIP1 isoform3 and FLAG-tagged CIKS . The immunoprecipitates were analysed by 
Western blot with anti-HA (upper panel). Expression of CIKS and both isoforms of LRRFIP1 
was confirmed by western blot with anti-HA ( lower panel) and anti-FLAG (middle panel) Abs,  
respectively.
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Figure 8:Identification of the domain of CIKS involved in the interaction with LRRFIP1 
isoform 3. HEK 293 were trasfected with an expression plasmid encoding HA-tagged 
LRRFIP1 isoform 3 and FLAG-tagged CIKS full-length or different deletion mutants. The 
immunoprecipitates were analysed by Western blot with anti-HA (upper panel). Expression of 
CIKS and LRFFIP1 isoform 3 was confirmed by western blot with anti-HA (middle panel) and 
anti-FLAG (lower panel) Abs, respectively.
Next, we investigated the region of LRRFIP1isoform 3 involved in the 
binding  to  CIKS.  We  performed  a  co-immunoprecipitation  assay  between 
FLAG-CIKS and HA-tagged LRRFIP1 isoform 3 full length or bearing two 
different mutations. Fig. 9  shown that LRRFIP1 isoform3 interacts with CIKS 
by its N-terminus domain.
LRRFIP1 isoform 3 regulates NF-B and AP1.
To investigate  if  LRRFIP1 was  interfering  with  some of  the  CIKS-
mediated functions, we performed a Luciferase assay evaluating the activity of 
a NF-B- and AP-1-driven reporter plasmids. HEK-293 were trasfected with 
either a NF-κB reporter plasmid, or an AP-1 reporter plasmid in the presence of 
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Figure 9:Mapping of LRRFIP1 isoform 3 interaction with CIKS. HEK 293 were transfected 
with different expression plasmids for HA-tagged LRRFIP1 isoform 3 (wt or LRRFIP1 
isoform3 1-240 that lose C-terminal portion, or LRRFIP1 isoform3 228-428 that lose N-
terminal portion.) and FLAG-tagged CIKS. The immunoprecipitates were analyzed by Western  
blot with anti-HA Ab (upper panel). Expression of CIKS and LRRFIP1 isoform3 was 
confirmed by western blot with anti-HA (middle panel) and anti-FLAG (lower panel) Abs, 
respectively.
a plasmids encoding CIKS with or without the plasmid encoding LRRFIP1 
isoform 3. As shown in fig.10, over-expression of CIKS strongly activated the 
transcription activity of both NF-B and AP-1. In contrast, over-expression of 
LRRFIP1 isoform 3 did not affect the activation of both reporter genes. When 
CIKS and LRRFIP1 isoform 3 were co-expressed, the CIKS-mediated NF-κB 
and AP-1 activation were not affected.
  
In order to investigate if LRRFIP1 was involved in the regulation of the 
IL-17 signaling,  we generated MEF stable clones over-expressing LRRFIP1 
isoform 3.  Fig11 shows two of  the clones  we isolated,  expressing different 
level of LRRFIP1.
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Figure 10:LRRFIP1 is unable to activate NF-B and AP-1 after trasfection. A, Luciferase 
activity of HEK293 cells transfected with Ig-B-luciferase reporter plasmid (A) or AP-1 
reporter plasmid (B) and renilla luciferase palsmid, together with plasmid expressing CIKS or 
LRRFIP1 isoform 3. 
In these cells we evaluated the promoter activity of NF-Band AP-1 
after  stimulation  with  IL-17  and  TNF-.  Cells  were  transfected  with  the 
indicated  reporter  plasmid  (Fig  12),  and  24h  after  trasfection,  cells  were 
stimulated for 4h with IL-17, TNF- or both cytokines. As shown in fig.12, 
treatment  of  mock  transfected  cells  with  TNF  or  IL-17  resulted  in  the 
activation  of  both  NF-κB  and  AP-1  reporter  plasmid.  Treatment  with  both 
cytokines  further  increased  the  reporter  plasmids  activation,  due  to  the 
synergistic  effect  of  TNF  and  IL-17.  In  the  two  clones  overexpressing 
LRRFIP1  isoform  3,  while  the  TNF-induced  NF-κB  and  AP-1  activation 
proceeds unhampered, both the IL-17-induced and the TNF plus IL-17 induced 
NF-κB and AP-1 activation was almost completely blocked (Fig12A and B).
This  results  together  with  the  data  reported  in  fig  11,  suggest  that 
LRRFIP1 isoform3 is interfering with the IL-17 pathway at a level upstream of 
CIKS.
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Figure 11:single stable clones of LRRFIP1 isoform3. Expression of LRRFIP1 isoform3 was 
confirmed by western blot with anti-HA (upper panel). The lower panel shows the 
normalization by -actin.
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Figure 12:LRRFIP1 decreases NF-κB and AP1 activation after IL-17 stimulation. Relative 
reporter activity was evaluated in MEF and single stable clones after stimulation of IL-17, 
TNF- or IL-17 plus TNF-
LRRFIP1 is involved in the IL-17-induced gene expression.
Given  that  LRRFIP1  interacted  with  CIKS  and  its  overexpression 
decreased  the  activity  of  NF-κB and AP1 induced by IL-17,  we sought  to 
investigate if LRRFIP1 was able to modulate the expression levels of different 
IL-17-induced  genes.  We  treated  control  MEF  and  two  stable  clones 
overexpressing LRRFIP1 with IL-17, and after 4 hours cells were harvested, 
RNA extracted, and analyzed by Real Time PCR. We evaluated the expression 
levels of CXCL1 and IL6 two of the genes induced by IL-17 stimulation. As 
shown  in  figure  13,  over-expression  of  LRRFIP1  isoform  3  resulted  in  a 
decrease of mRNA levels of CXCL1 and IL6 compared with wild type cells. 
To  confirm  this  result,  we  knocked  down  LRRFIP1  isoform  3 
expression in  MEF by using  siRNA. As shown in fig.14 the expression of 
LRRFIP1  isoform  3  was  decreased  by  about  60%  in  the  interfered  cells 
compared to the control. In these cells we evaluated the expression of CXCL1 
and IL6 genes by Real Time PCR after IL-17 stimulation.  As shown in figure 
14  in  the  knocked down cells  stimulation  with  IL-17 resulted  in  increased 
expression levels of both CXCL1 and IL6 genes compared to control cells. 
These results suggest that LRRFIP1 is acting as a negative regulator of the IL-
17 signalling.
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Figure 13: Over-expression of LRRFIP1 decreased mRNA levels of CXCL1 and IL6 after IL-17  
stimulation. Real Time PCR analysis of CXCL1 expression (A) and IL6 (B) in MEF and in 
single stable clones unstimulated and stimulated for 4h with IL-17. 
LRRFIP1 displaces CIKS from the IL-17 receptor.
To further characterize the direct involvement of LRRFIP1 in the IL-17 
pathway and to shed light on the molecular mechanism used by LRRFIP1 to 
negatively  regulates  the  IL-17  pathway,  we  investigated  the  interaction 
between LRRFIP1 isoform 3 with CIKS and IL-17 receptor. We transfected 
HEK293 with the indicated expression vector (Fig.  15), immunoprecipitated 
FLAG-tagged  IL-17R  and  looked  for  co-immunoprecipitating  HA-tagged 
proteins. As shown in figure 15, IL-17R was not interacting with LRRFIP1 
isoform 3. Interestingly, in the presence of LRRFIP1 the amount of CIKS co-
immunoprecipitating with the IL-17 receptor was sharply decreased. This result 
suggest that LRRFIP1 is able to negatively regulates IL-17 pathway interfering 
with the interaction between IL-17R and CIKS.
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Figure 14: Knock-down of LRRFIP1 increases the expression levels of CXCL1 and IL6 after 
IL-17 stimulation. SiRNA scramble and siRNA LRRFIP1 were transfected in MEF cells. 72h 
after transfection cells were stimulated 4h with IL-17. A LRRFIP1 isoforms 3 was down-
regulated assessed by Real Time PCR. B,C, down-regulation of LRRFIP1 in stimulated cells 
increased mRNA levels of CXCL1 and IL6.
To confirm this result, we evaluated the interaction between the CIKS 
and the IL-17 receptor, in the presence of increasing amount of LRRFIP1. As 
shown  in  fig.  16,  by  in  the  presence  of  increasing  amounts  of  LRRFIP1 
isoform 3, the amount of CIKS co-immunoprecipitating with the IL-17R was 
gradually decreased, further suggesting that LRRFIP1 negatively regulated IL-
17 signaling by interfering with the interaction between CIKS and the receptor. 
33
Figure 15:  LRRFIP1 isoform 3 influences the interaction between IL-17R and CIKS. HEK 293  
were transfected with both expression plasmids for HA-tagged LRRFIP1 isoform 3, HA-tagged  
CIKS  and FLAG-tagged IL-17R. The immunoprecipitates were analyzed by Western blot with 
anti-HA Ab (upper panel). Expression of CIKS and LRRFIP1 isoforms was confirmed by 
western blot with anti-HA (middle panel) while the expression of IL-17R was confirmed by 
western blot with anti-FLAG (lower panel) Abs, respectively.
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Figure 16: HEK 293 were trasfected with expression plasmids encoded for HA-tagged 
LRRFIP1 isoform 3, HA-tagged CIKS and FLAG-tagged IL-17R. We transfected the same 
quantity of FLAG-IL-17R and HA-CIKS while we transfected decreasing amount of LRRFIP1 
isoform 3, from 2 to 0,25. The immunoprecipitates were analysed by Western blot with anti-
HA (upper panel). Expression of CIKS and LRFFIP1 isoform 3 was confirmed by western blot 
with anti-HA (middle panel) and anti-FLAG (lower panel) Abs, respectively.
DISCUSSION
The goal of this study was to indentify proteins interacting with CIKS 
to  better  understand  the  molecular  mechanism regulating  the  inflammatory 
responses mediated by the IL-17. IL-17 is a pro-inflammatory cytokine that 
plays  an  essential  role  in  host  defense  against  microbial  infections  and  is 
implicated in various inflammatory conditions such as autoimmune diseases, 
metabolic  disorders  and  cancer.  In  the  present  study  we  present  evidence 
identifying LRRFIP1 isoform 3 as a new CIKS-interacting protein, functioning 
as  a  negative  regulator  of  the  IL-17 pathway.  Overexpression  of  LRRFIP1 
isoform 3 blocks the IL-17 induced expression of  cxcl1 and  il-6, two of the 
major IL-17 target genes, via inhibition of NF-κB and AP-1. Indeed, cells in 
which the expression of LRRFIP1 isoform 3 is knocked-down, the expression 
level  of  these two genes  after  IL-17 stimulation is  strongly  enhanced.  This 
inhibitory function is possibly due to the ability of LRRFIP1 to interfere with 
the binding of CIKS to the IL-17 receptor. In fact, in the presence of increasing 
amounts of LRRFIP1 isoform 3, the binding of CIKS to the IL-17R is blocked. 
It is then possible to suppose that LRRFIP1 isoform 3 inhibits the interaction 
between  CIKS  and  the  IL-17R  to  block  IL-17  signaling.  In  addition,  the 
activation  of  NF-κB  mediated  by  CIKS  overexpression  is  not  affected  by 
LRRFIP1, further suggesting that this inhibition take place at a level  upstream 
to CIKS, possibly at the level of the IL-17 receptor. It is tempting to speculate 
that  upon IL-17 stimulation,  CIKS is  recruited  to  the  IL-17 receptor  via  a 
SEFIR  domain-mediated  interaction,  to  initiates  a  cascade  of  events 
culminating  in  the  activation  of  downstream  effectors.  After  stimulation, 
LRRFIP1 isoform 3 displace CIKS from the cytoplasmic domain of the IL-17 
receptor to block signaling. We are currently investigating this hypothesis, and 
we have some preliminary data suggesting that the expression of  LRRFIP1 
isoform 3 is induced by IL-17 (see also fig 14A). 
The signaling of IL-17 is under tight control to avoid persistent 
inflammation. Different mechanisms negatively regulating IL-17 signaling 
have been described so far. Some act blocking the transcription factor 
C/EBPthat once phosphorylated is not longer able to drive the transcription 
of proinflammatory genes induced by IL-17. Other mechanisms inhibit the 
formation of the IL-17R-CIKS-TRAF6 complex. In fact, it has been 
demonstrated that TRAF4 and TRAF3, compete with TRAF6 for CIKS 
binding, thus blocking the IL-17 mediated signaling. Similarly, the IL-17RD, 
one of the member of the IL-17 receptor family, interacts with IL-17RA and 
CIKS through SEFIR-SEFIR domain interaction, to disrupt CIKS-TRAF6 
binding and inhibiting NF-κB activation. Also two kinases, IKKi and TBK1, 
that phosphorylate CIKS on three Ser residues, are able to decrease the 
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interaction between CIKS and TRAF6. More recently, IL-17 signaling was 
shown to be negatively regulated by the ubiquitin-specific protease USP25, one 
subfamily member of deubiquitinating enzyme. USP25 directly removes IL-17 
induced ubiquitination of TRAF5 and TRAF6, and consequently suppressed 
both TRAF6 dependent NF-B activation and TRAF6 independent mRNA 
stabilization pathways in IL-17R signaling (Gu et al., 2013; Song and Qian, 
2013) . In this study we described an additional mechanism downregulating IL-
17 signaling. LRRFIP1 isoform 3 blocks the interaction between CIKS and IL-
17R thereby preventing CIKS to activate the IL-17 pathway. Why different 
mechanisms regulating IL-17 signaling exist? One possible explanation is that 
the inflammatory response needs to be tightly regulated to avoid excessive 
inflammation then, the existence of multiple mechanisms acting at different 
levels, i.e. proximal to the receptor and directly into the nucleus, are needed to 
ensure correct regulation of the inflammatory responses. In fact, the regulation 
of the NF-κB activation, the master transcription factor regulating 
inflammation also relies on multiple mechanisms (Ruland, 2011) .
Our findings describe for the first time a function related to the isoform 
3 of  LRRFIP1 in innate  immunity.  While  an  involvement  of  the other  two 
isoforms of LRRFIP1 in innate immunity have been reported, no function was 
associated to isoform 3 to date. Indeed, isoform 1 has been reported to be a 
cytosolic DNA and RNA sensor inducing the activation of IFN- It can also 
act  as  a  transcriptional  repressor  blocking transcription of the TNF- gene. 
These  two  functions  seems  to  be  in  contrast  to  each  other  as  interferone 
induction is a canonical response of the innate immune system, while blocking 
TNF  transcription  halts  the  innate  response.  This  discrepancy  might  be 
explained by the different cell lines used in the two studies, or may simply 
reflects the different subcellular localization of isoform 1. When isoform 1 is in 
the  cytosol,  acts  as  sensor  of  foreign  nucleic  acids,  activating  the  innate 
immune response, while when is in the nucleus, acts to terminate inflammation. 
Isoform 2 has been reported to interact with Myd88 and to positively regulate 
Toll-like receptor signaling. Our results assign a new function to isoform 3 and 
expand the functions of the LRRFIP1 family in regulating immune responses. 
It  is  interesting that different splice isoforms of the  lrrfip1 gene,  give raise 
different proteins structurally not fully related,  to regulate different pathways 
of the immune system.
In summary, we have identified a previously not reported association 
between CIKS and LRRFIP1, and we provide evidence that LRRFIP1 isoform 
3 negatively regulates IL-17 pathway.
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NGAL Controls the Metastatic Potential of Anaplastic
Thyroid Carcinoma Cells
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Context: We have previously identified neutrophil gelatinase-associated lipocalin (NGAL) as one
of the genes mediating the oncogenic activity of nuclear factor-B in human anaplastic thyroid
carcinomas (ATCs).
Objectives: To further investigate the role of NGAL in thyroid cancer, we established NGAL
knocked-down and NGAL overexpressing ATC cell lines.
Results:We found that the ability of NGAL knocked-down cells to degradeMatrigel in a transwell
invasionassay and to form lungmetastasis innudemicewasdecreased. BecauseNGALbindsmatrix
metalloproteinase-9 (MMP-9), to form a macromolecular complex involved in the regulation of
metastatic spread of cancer cells and given the strong expression of both genes in tissue specimens
from human ATCs, we analyzed the MMP-9 enzymatic activity in NGAL-null ATC cells. Enzymatic
immunoassays show that MMP-9 activity is reduced in NGAL-null ATC cells, even if its expression
is not affected by NGAL inhibition. Ectopic expression of NGAL in an ATC cell line not expressing
NGALdeterminesan increaseof itsmetastaticproperty. Theuseofamutated formofNGAL,unable
to bind MMP-9, has no positive effect on the invasive potential of ATC cells and does not improve
the MMP-9 enzymatic activity.
Conclusions:Our results indicateNGALas a novel target of nuclear factor-Bprometastatic activity
in thyroid cancer through enhancement ofMMP-9 enzymatic activity. (J Clin EndocrinolMetab 98:
0000–0000, 2013)
One of the most problematic aspects of cancer is rep-resented by metastatic disease that is largely incur-
able because of its systemic nature and the increased re-
sistance of metastatic cells to chemo- or radiotherapy. In
the vastmajority of cases, themortality from cancer is due
to metastases, not to the primary tumor (1, 2). Therefore,
a great effort has been attempting to understand the mo-
lecular mechanisms underlying the metastatic process to
identify novel targets for more effective therapeutic inter-
vention. Metastasis development is a very complex pro-
cess which requires a number of coordinated steps to suc-
cessfullypromote theonsetof secondaryneoplastic lesions
at organs distant from primary tumor. The initial event of
metastatic cascade is represented by local invasion of pri-
mary tumor cells to adjacent tissues. This process is
achieved by cancer cells via degradation of basement
membrane, a specialized extracellular matrix that plays
vital roles in organizing epithelial tissues. The degradation
of basement membrane occurs by proteolysis of extracel-
lular matrix components mediated by the activity of a
family of zinc and calcium dependent endopeptidases col-
lectively termed matrix metalloproteinases (MMPs) (3).
One of themost importantmetalloproteinases involved in
the invasion process isMMP-9, a 92-kDa protease able to
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degrade a broad range of substrates including collagens,
fibronectins, and laminins (4).MMP-9 is highly expressed
inmany human tumors, especially ofmore aggressive phe-
notype, and its levels generally correlate with a poor prog-
nosis (5–8). Its enzymatic activity is, at least partially,
regulated by neutrophil gelatinase-associated lipocalin
(NGAL), via the formation of a macromolecular complex
that allowsMMP-9 to preserve its proteolytic activity (9).
We have previously demonstrated that nuclear fac-
tor-B (NF-B) is strongly activated in human thyroid
cancer in which it plays an important role, given that the
inhibition of its activity in anaplastic thyroid carcinoma
(ATC) cells blocks their oncogenic potential (10). In the
effort to identify target genes of NF-B activity in thyroid
cancer, we found that NGAL is able to recapitulate some
of protumorigenic functions of NF-B in these tumors,
such as the ability to protect ATC cells from growth fac-
tors deprivation-induced apoptosis (11). NGAL, also
known as lipocalin-2, is a member of the large family of
lipocalins, a group of small extracellular proteins with
great functional diversity (12). It is overexpressed in a
numberofhuman tumors, includingbreast (13), lung (14),
colon (15), ovary (16), andpancreas (17) carcinomas. Sev-
eral studieshavedemonstrated thatNGALhasprotumori-
genic activity that occurs through the enhancementof neo-
plastic cell survival and proliferation, very likely due to its
iron-carrier function. In addition, NGAL contributes to
cancer by promoting the metastatic potential of tumor
cells because of its ability to protect MMP-9 from auto-
degradation (9, 18).
We found a strong coexpression of both NGAL and
MMP-9 in tissue specimens fromprimary humanATCs so
thatwedecided to investigate the roleofNGALin theATC
metastatic process by modulating its expression in two
ATC cell lines, BHT101 and Act1.
Materials and Methods
Cell culture and biological reagents
BHT101andAct1 cellswere kindly provided byProfessorM.
Santoro, “Federico II” University of Naples. To knock down
NGAL expression, BHT101 cells were infected with pLL 3.7
lentiviral vector containing double-strandedoligonucleotides se-
quences derived from the human NGAL in forward and reverse
orientation, separated by a 7-bp spacer region (caagaga) to allow
the formation of the hairpin structure in the expressed small
interfering RNAs (siRNAs): NGAL sc-siRNA, sense strand, 5-
CCATCTATGAGCTGAAAGAcaagagaTCTTTCAGCTCATA
GATGG-3, antisense strand, 5-CCATCTATGAGCTGAAAG
AtctcttgTCTTTCAGCTCATAGATGG-3; NGAL siRNA1,
sense strand, 5-GGGAATGCAATTCTCAGAGTTcaagagaAA
CTCTGAGAATTGCATTCCC-3, antisense strand, 5-GGGA
ATGCAATTCTCAGAGTTtctcttgAACTCTGAGAATTGCAT
TCCC-3; NGAL siRNA2, sense strand, 5-GGACTTTTGTT
CCAGGTTGTTcaagagaAACAACCTGGAACAAAAGTCC-3,
antisense strand, 5-GGACTTTTGTTCCAGGTTGTTtctcttgAA
CAACCTGGAACAAAAGTCC-3. Act1 cells were infected with
pLENTI CMV GFP-2A-PURO vector (ABM, Richmond, British
Columbia, Canada) alone or containing the cDNA coding for hu-
man wild-type or mutated NGAL fused in frame with the hemag-
glutinin (HA) tag. All cell lines were grown in DMEM (Sigma, St.
Louis, MO) supplemented with 10% fetal bovine serum (Sigma).
Anti-HA (sc-805 and sc-7392) and antiactin (sc-8432) were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA),
anti-FLAG (F7425 and F3165) was from Sigma, and anti-NGAL
(AF1757) was from R&D Systems (Minneapolis, MN).
Patients
The study has been approved by the local ethics committees.
Informed consent of the patients had been obtained before their
inclusion in the study. Five cases of surgically resected ATCs and
two specimens of the normal controlateral thyroid lobe from
surgically resectedbenignadenomaswere analyzed for their abil-
ity to express NGAL and MMP-9 mRNAs. The clinicopatho-
logical characteristics of the ATC selected cases are shown in
Supplemental Table 1, published on The Endocrine Society’s
Journals Online web site at http://endo.endojournals.org.
mRNA quantification by real-time RT-PCR
Real-time RT-PCR was carried out with cDNAs reverse tran-
scribed from total RNA by using GoTaq qPCR master mix
(Promega, Madison, WI) and Bio-Rad CFX Manager software
(Bio-Rad Laboratories, Segrate, Milan, Italy), according to manu-
facturers’ procedure. The primers used were: glyceraldehyde-3-
phosphatedehydrogenase,forward,5-AAACAGAAGGCAGCTT
TACGATG-3, reverse,5-AAATGTTCTGATCCAGTAGCG-3;
NGAL, forward, 5-GAAGACAAAGACCCGCAAAAG-3, re-
verse, 5-CTGGCAACCTGGAACAAAAG-3; and MMP-9, for-
ward, 5-CGAACTTTGACAGCGACAAG-3, reverse, 5-CACT
GAGGAA TGATCTAAGCCC-3.
Immunoprecipitation and Western blots
For immunoprecipitation of transfected proteins, human em-
bryonic kidney (HEK) 293 cells (3 106) were transiently trans-
fected by using Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA), and 24 h after transfection, cells were lysed in Triton
X-100 lysis buffer (20 mMHEPES, pH 7.4; 150 mMNaCl; 10%
glycerol; 1% Triton X-100; and Complete protease inhibitor
mixture). After an additional 15 min on ice, cell extracts were
centrifuged for 10 min at 14,000  g at 4 C, and supernatants
were incubated for 4 h at 4 C with anti-HA antibodies bound to
agarose beads (Sigma). The immunoprecipitates were washed
five times with Triton X-100 lysis buffer and subjected to
SDS-PAGE.
For Western blots, 20 g of total proteins from cell lysates
or supernatants was analyzed by 10% SDS-PAGE and blotted
onto nitrocellulose membrane (Schleicher & Schuell, What-
manGmbH,Dassel, Germany). Filters were blocked for 1 h 30
min at room temperature with 5% nonfat dry milk in TBST
buffer [10 mM Tris-HCl (pH 8), 0.1% Tween 20, 150 mM
NaCl] and incubated with 1:2000 dilution of anti-HA, anti-
FLAG, anti-NGAL, or antiactin antibodies for 1 h 30 min.
After TBST washing, blots were incubated for 1 h with horse-
radish peroxidase-conjugated secondary antibodies (NXA931;
AmershamBiosciences,Buckinghamshire,UK)diluted1:5000 in
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TBST buffer and then revealed by enhanced chemiluminescence
(Amersham Biosciences).
Matrigel invasion assays
Cell invasion was examined using a reconstituted extracellu-
lar matrix (Matrigel; BD Biosciences, Bedford, MA). Polycar-
bonatemembranes (8mmpore size) on the bottoms of the upper
compartment of the transwells (6.5 mm; Costar, Cambridge,
MA) were coated with 1.2 mg/ml Matrigel. The 1 105 cells in
100 l of serum-free Opti-MEM I (Invitrogen), alone or added
with recombinant NGAL (11), were placed on the Matrigel-
coated polycarbonate membrane in the upper compartment,
whereas 600 l of Opti-MEM I supplemented with 10% fetal
bovine serum was added to the lower compartment. The plates
were incubated at 37 C in a 5%CO2 atmosphere saturated with
H2O for 24 h. At the end of incubation, the cells andMatrigel at
the upper side of the polycarbonate filter were mechanically re-
moved. Cells that had invaded the Matrigel and migrated to the
lower side of the filter were fixed with 11% glutheraldeyde for
15 min at room temperature, washed three times with PBS, and
stained with 0.1% crystal violet-20% methanol for 20 min at
room temperature. After three PBS washes and complete drying
at room temperature, the crystal violet was solubilized by im-
merging the filters in 300 l of 10% acetic acid. The concentra-
tion of the solubilized crystal violet was evaluated as absorbance
at 590 nm. Experiments were performed at least in triplicate.
Results are SD of at least three separate experiments.
In vivo experiments
To analyze in vivo the metastatic activity of neoplastic cells,
1 107 cells were resuspended in 200l of PBS and injected into
the tail vein of 6-wk-old athymic mice divided into four groups
of six animals each one. Groups were injected as follows: group
1, PBS alone; group 2, BHT cells; group 3, BHT pLL sc-siRNA
cells; and group4, BHTpLL siRNA2. Fourweeks after injection,
mice were killed and lung metastasis was analyzed by standard
hematoxylin and eosin staining.
Analysis of MMP-9 activity
The quantitative determination of human active MMP-9 in
conditioned media from NGAL-proficient and -deficient
BHT101 and Act1 cell lines was performed by Fluorokine E
immunoassay, according to the manufacturer’s instructions
(R&DSystems). The relative fluorescence unitswere determined
with the PerkinElmer LS50B luminescence spectrometer (New
York, NY) using an excitation wavelength of 320 nm and an
emissionwavelength of 405 nm. Experimentswere performed at
least in triplicate. Results are SD of at least three separate
experiments.
Statistics
Datawere analyzedwith ANOVA and a Student’s t test anal-
ysis. Data are presented as the means  SD. P  0.05 was con-
sidered significant.
Results
MMP-9 and NGAL are overexpressed in human
ATCs
We have previously shown (11) that NGAL is strongly
expressed in human thyroid carcinomas, especially that of
the anaplastic type. Because it is known that in many tu-
morsNGAL expression parallels that ofMMP-9 (19–21),
we verified whether both genes were overexpressed in hu-
man thyroid tumors from the same tissue specimen. As
shown in Fig. 1A,MMP-9 expression is clearly more pro-
nounced in human ATCs than in normal thyroid tissues,
as assessed by quantitative RT-PCR (qRT-PCR) analysis,
and, importantly, it overlaps that of NGAL in the same
tissues (Fig. 1B), indicating that both genes are highly ex-
pressed in the most aggressive and metastatic types of hu-
man thyroid carcinomas.
Establishment of knocked-down and
overexpressing NGAL anaplastic thyroid carcinoma
cell lines
To study the role of NGAL in the metastatic activity of
ATC cells, we modulated its expression in two ATC cell
lines, BHT101 and Act1, that show different levels of
NGAL expression. BHT101 cells express high levels of
NGAL and secrete the protein in the culture medium,
whereas Act1 cells do not express NGAL that is not de-
tectable either in the whole cell extract or in the culture
medium (Fig. 2, A and B). Therefore, we knocked down
NGAL in BHT101 cells by infecting cells with two differ-
ent lentiviruses containing siRNAsequences that bind two
different regions of NGAL mRNA (pLL siRNA1 and -2).
In parallel, we ectopically expressed NGAL in Act1 cells
by infecting cells with a lentivirus carrying the cDNA en-
FIG. 1. MMP-9 and NGAL expression in primary human ATC
specimens. qRT-PCR of MMP-9 (A) and NGAL (B) in normal thyroid
(NT1 and NT2) and ATCs (ATC1, ATC2, ATC3, ATC7, and ATC8) from
human specimens. The relative amount of MMP-9 and NGAL mRNA
was normalized to the glyceraldehyde-3-phosphate dehydrogenase
mRNA. *, P  0.001; **, P  0.0001; ***, P  0.00001; ****, P 
0.000001.
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coding for humanNGAL.BHT101cells infectedwithpLL
siRNA1 and pLL siRNA2 showed a strong decrease of
NGAL expression compared with uninfected cells and to
control scrambled siRNA (Fig. 2A). The ectopic expres-
sion ofNGAL inAct1 cells was successfully achieved both
in lysates and extracellular media, as shown in Fig. 2B.
In addition, we also infected Act1 cells with a mutated
formofNGAL (C87R), carrying a substitution of cysteine
residue in position 87 with an arginine residue (C87R)
(Fig. 2B). This mutation impairs the ability of NGAL to
form thedisulfide bridgewithMMP-9, thereby interfering
with NGAL-mediatedMMP-9 protection from auto-deg-
radation and preventing association of tissue inhibitor of
metalloproteinase-1 with MMP-9 N-terminal domain
(22). To test the effectiveness of this substitution, we tran-
siently cotransfected HEK293 cells with FLAG-MMP-9
andNGAL-HAorwithFLAG-MMP-9andNGALC87R-
HA, respectively, and we coimmunoprecipitated them
with anti-HA antibodies. Western blot analysis of immu-
noprecipitated proteins with anti-FLAG antibodies re-
vealed that only wild-type NGAL-HA was able to bind
FLAG-MMP-9, whereas the mutated NGAL C87R-HA
was completely unable to interact with the metalloprotei-
nase (Fig. 3).
NGAL enhances the invasiveness of BHT101 and
Act1 cells
BothNGALknocked-downandNGALoverexpressing
cell lineswere tested for their ability to degradematrigel in
a transwell invasion assays. As shown in Fig. 4, all BHT
cell lines migrated through the transwell at similar extent,
independently of the presence of NGAL in the culture me-
dium (Fig. 4, A–C, left panels). However, they not de-
gradedmatrigelwith the sameefficiency (Fig. 4,A–C, right
panels). In particular, knocking down NGAL expression
determined the decrease of BHT cells invasiveness com-
pared with that of parental and sc-siRNA BHT cells, as
FIG. 3. The substitution of cysteine residue in position 87 with
arginine (C87R) impairs NGAL binding to MMP-9. HEK293 cells were
transfected with constructs encoding MMP-9, wild-type (WT), and
mutated (C87R) NGAL. Cell lysates were immunoprecipitated (IP) with
anti-HA antibodies (NGAL) and Western blotted (WB) with anti-FLAG
to reveal the coprecipitation of MMP-9 and NGAL. The presence of HA
and FLAG proteins in total lysates is shown in lower panels.
FIG. 2. Modulation of NGAL expression in ATC cell lines. Western blot of NGAL on conditioned media and lysates from BHT101 cells uninfected
and infected with pLL 3.7 NGAL siRNA1, siRNA2, or scrambled (sc) siRNA (A) and from Act1 cells uninfected and infected with pLENTI alone,
pLENTI NGAL-HA, or pLENTI NGAL C87R-HA (B). The expression levels of NGAL protein from lysates were normalized on actin content (A and B,
bottom panels), whereas those of conditioned media were normalized on total protein content determined by a Bradford assay (Bio-Rad
Laboratories).
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assessed by the reducednumber of bothBHTpLL siRNA1
and siRNA2 cells that degraded matrigel (Fig. 4D). The
addition of NGAL-containing conditioned medium or re-
combinant NGAL to the upper chamber of transwells re-
stored the invading activity of BHT pLL siRNA1 and
siRNA2 cells (Fig. 4, B–D). On the other hand, the ectopic
expression of NGAL in Act1 cells induced an increase of
their invasiveness, as assessed by amore pronounced abil-
ity of NGAL-expressing Act1 cells to degrade matrigel
compared with the parental and control vector cells (Fig.
FIG. 4. In vitro invasive properties of NGAL-proficient and -deficient ATC cell lines. Parental and infected BHT101 (A–C) and Act1 (E) cell lines
were used to analyze their ability to degrade Matrigel (BD Biosciences) in transwell assays. The extent of invasive potential was measured as the
number of Matrigel degrading cells on total migrating cells (D, *, P  0.01, **, P  0.001; and F, *, P  0.001). SFM, Serum-free medium; CM,
conditioned medium; rNGAL, recombinant NGAL.
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4, E and F). Importantly, Act1 cells expressing the C87R
NGAL mutant reversed the proinvading effects of wild-
typeNGAL, suggesting that interferingwith the formation
of NGAL/MMP9 complex is important in regulating the
prometastatic activity of MMP-9.
To confirm these results in vivo, we
injected parental and NGAL knocked-
down BHT101 cells in the tail vein of
athymic mice, which represents a pref-
erential way of access for tumor cells
migration to future metastatic sites, i.e.
lung and liver. Figure 5 shows the he-
matoxylin-and-eosin staining of lung
metastases from mice injected with un-
infected BHT101, BHT pLL sc-siRNA,
and BHT pLL siRNA2 cells. All three
cell lines gave rise to lung metastases
but at different extent. Inparticular, the
number of lung metastases from
BHT101NGAL-null cells injectedmice
were lower than those originated from
parental and scrambled BHT101 cells
(Fig. 5, A and B).
These results suggest that the pres-
ence of functional NGAL increased
the metastatic potential of ATC cells,
in vitro and in vivo, very likely thr-
ough the improvement of MMP-9
activity.
MMP-9 enzymatic activity is enhanced by the
presence of NGAL
To test our hypothesis, we evaluated the MMP-9 ac-
tivity in the parental and infected BHT101 and Act1 cell
lines by an immunoenzymatic assay. To this purpose, cells
FIG. 5. In vivo analysis of metastatic activity of NGAL-proficient and -deficient ATC cells.
Parental and infected BHT101 cells were injected in athymic mice tail vein to analyze their
ability to form lung metastasis (A). The number of metastatic lesions in the lung was
determined for each group of injected mice (B). *, P  0.0001.
FIG. 6. Determination of MMP-9 activity in conditioned media from ATC cell lines. Conditioned media from parental and infected BHT101 (A, *,
P  0.001, **, P  0.0001) and Act1 (C, *, P  0.001, **, P  0.0001) cell lines were collected to determine the concentration of active MMP-9.
qRT-PCR analysis showed that no difference of MMP-9 expression was detected among cell lines (B and D).
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were grown in serum-free medium, and after 48 h their
conditioned media were collected to measure the levels of
endogenous active MMP-9. As shown in Fig. 6A, the ab-
sence of NGAL in BHT101 cells determined a strong de-
crease of activeMMP-9 content compared with that mea-
sured in the extracellular medium of parental and
scrambled BHT101 cells. On the contrary, the concentra-
tion of active MMP-9 from the conditioned medium of
NGAL-overexpressingBHT101 cellswas higher than that
from conditioned media of control cells (Fig. 6C). Impor-
tantly, the presence of the mutated form of NGAL in
BHT101 extracellular medium had no effect on MMP-9
activity. The up- or down-regulation of enzymatic activity
in the different experimental systems was not dependent
on MMP-9 expression because RT-PCR analysis showed
that no differences of MMP-9 mRNA levels were detect-
able in the various cell lines (Fig. 6, B and D).
Discussion
In the present paper, we analyzed the role of NGAL in
promoting ATC tissue invasion through enhancement of
MMP-9 activity. The inhibition of NGAL expression,
which is strongly elevated in the same primary human
ATC showing high MMP-9 expression, decreases the in
vitro and in vivometastatic potential of BHT101ATCcell
line. This effect is the consequence of the reduced enzy-
matic activity of MMP-9 in the absence of NGAL. How-
ever, knocking downNGAL expression in BHT101 cells
does not completely abrogate the ability of these cells to
invade matrigel and to form lung metastasis (Figs. 4, A
and D, and 5, A and B). This is probably due to the
presence of a residual NGAL expression in BHT siRNA
cells, as assessed by Western blot (Fig. 2A), that still
preserves MMP-9 from autodegradation, as proven by
the partial but not absolute decrease of MMP-9 enzy-
matic activity in the extracellular medium of BHT
NGAL-null cells (Fig. 6A).
The importance of NGAL as regulator of ATC cells
metastatic potential is further supported by increased
MMP-9 enzymatic activity in the Act1 after ectopic ex-
pression of NGAL. In this case, the secretion of extracel-
lular NGAL improves the MMP-9 enzymatic activity of
Act1 cells causing the increased invasion throughmatrigel
in the transwell assay. This effect is clearly NGAL medi-
ated because Act1 cells overexpressing the C87R mutant
of NGAL show aMMP-9 activity and an invasive behav-
ior similar to those of control cells. The evidence of a basal
MMP-9 activity independent ofNGALexpression inAct1
cells (Figs. 4,D andE, and 6C) points out thatMMP-9 can
function in the absence of NGAL; even so, the presence of
NGAL significantly improves its enzymatic activity.
In the light of these findings, the strong coexpression of
NGAL and MMP-9 in primary human ATC suggests a
pro-metastatic role of NGAL/MMP-9 complex in aggres-
sive thyroid carcinomas. Anaplastic thyroid carcinomas
constitute themost undifferentiated type of thyroid cancer
withmarked invasive properties so that the presence of an
active NGAL/MMP-9 complex could explain in part the
metastatic potential of ATC cells. The biological impor-
tance of NGAL/MMP-9 complex in cancer has been ex-
tensively studied in other human tumors, such as breast
cancer (18, 23), esophageal (20) and oral (24, 25) squa-
mous cell carcinomas, cholangiocarcinomas (21), bladder
cancer (26), gastric cancer (19), and rectal cancer (27). In
these reports the activity of the complex generally corre-
lates with the more aggressive behavior of neoplastic cells
and, in themajority of cases, with a poor prognosis. Thus,
the role of NGAL/MMP-9 complex in metastatic thyroid
cancer, up to nownot yet elucidated, fits with that exerted
in other types of human tumors.
The identification of NGAL as a regulator of ATC-
induced metastasis adds a novel piece to the puzzle of
NF-B functions in thyroid cancer (10, 11, 28–31). In fact,
our previous results and the findings reported here indi-
cate that NF-B activity could influence the invasive po-
tential of ATC cells through the up-regulation of NGAL
other than ofMMP-9, whosemRNA transcription, as it is
known, is in part under NF-B control (32). This could
also explain why the expression of both genes is so ele-
vated inATCs inwhichNF-B is strongly activated. In this
way, NGAL could be viewed as a novel target gene of
NF-B-mediated metastatic activity of ATC cells and its
inhibitionas apotential tool for therapeutical intervention
in advanced ATC therapy without altering NF-B physi-
ological functions.
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